RSS

Mylan

A strategy for the development of a biosimilar to the vascular endothelial growth factor (VEGF) inhibitor treatment for various degenerative retinal diseases, aflibercept, has been announced by Momenta Pharmaceuticals and Mylan. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

The US Food and Drug Administration (FDA) has approved the first biosimilar for the treatment of certain breast and stomach cancers, Ogivri (trastuzumab-dkst). more

News

Global pharmaceutical company, Mylan, is joining in the battle to prevent HIV infection by delivering the world’s biggest pre-exposure prophylaxis (PrEP) implementation trial, which will target an estimated 10,000 high risk people. more

News

Global pharmaceutical company, Mylan, has announced that its partner Synthon has received European marketing authorisation approval for its generic, Glatiramer Acetate injection, to treat patients with relapsing forms of multiple sclerosis (MS). more

News

Mylan has launched the first bioequivalent alternative to GlaxoSmithKline’s Seretide Evohaler (salmeterol xinafoate/fluticasone propionate) under the brand name Sirdupla in the UK. more

News

To better understand where the generic market is heading, a panel discussion was held with CEOs of top generic pharmaceutical companies and key financial analysts at this year’s Generic Pharmaceutical Association (GPhA) annual meeting. more

Technology